Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00016679
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
2001-05-24
Brief Title:
1-Octanol to Treat Essential Tremor
Sponsor:
National Institute of Neurological Disorders and Stroke NINDS
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Dose Finding Study of 1-Octanol in Essential Tremor
Status:
COMPLETED
Status Verified Date:
2004-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will determine the optimal dose of 1-octanol that will safely reduce tremors in patients with essential tremor-a disorder in which the hands and sometimes the head shake involuntarily Current treatments may be ineffective or produce unwanted side effects Ethanol the chemical in beer and wine that causes intoxication reduces tremor in many patients but patients generally dont use it regularly because it interferes with daily activities Laboratory studies show that 1-octanol a drug that is similar to ethanol may have the same beneficial effect on tremors with less likelihood of intoxication
Patients 21 years of age and older with essential tremor may be eligible for this 10-day study Candidates will be evaluated with a neurological examination blood tests urinalysis and electrocardiogram EKG Those enrolled will be admitted to the hospital for 4 days for 1-octanol administration and monitoring On day 1 patients will have a medical history and physical examination A catheter a thin plastic tube will be placed in a vein of the forearm for sampling blood Patients will take one 1-octanol capsule at one of seven doses by mouth and will be monitored for tremors and drug side effects Blood will be sampled periodically in the first 3 hours to determine 1-octanol blood levels On days 2 and 3 patients will be monitored for additional side effects On days 3 and 4 laboratory tests blood and urine will be done to evaluate liver and kidney function On day 4 the catheter will be removed and the patient will be discharged from the hospital A follow-up visit will be scheduled 1 week after discharge for a physical examination and blood urine and EKG tests
Patients 21 years of age and older with essential tremor may be eligible for this 10-day study Candidates will be evaluated with a neurological examination blood tests urinalysis and electrocardiogram EKG Those enrolled will be admitted to the hospital for 4 days for 1-octanol administration and monitoring On day 1 patients will have a medical history and physical examination A catheter a thin plastic tube will be placed in a vein of the forearm for sampling blood Patients will take one 1-octanol capsule at one of seven doses by mouth and will be monitored for tremors and drug side effects Blood will be sampled periodically in the first 3 hours to determine 1-octanol blood levels On days 2 and 3 patients will be monitored for additional side effects On days 3 and 4 laboratory tests blood and urine will be done to evaluate liver and kidney function On day 4 the catheter will be removed and the patient will be discharged from the hospital A follow-up visit will be scheduled 1 week after discharge for a physical examination and blood urine and EKG tests
Detailed Description:
Essential tremor is a very common movement disorder affecting approximately 14 of the population Response to medications such as beta blockers and mysoline may be only partial or be accompanied by intolerable side effects Roughly 80 of patients have significant tremor reduction to ethanol although daily use of this as a treatment has potentially serious social and legal consequences The leading hypothesis for the pathophysiology of essential tremor is unmasking of spontaneous oscillation of neurons in the inferior olive Both ethanol and 1-octanol have been shown to reduce these spontaneous oscillations in an animal model of essential tremor however 1-octanol dose this at a dose much lower than an intoxicating dose suggesting that it may be useful in the treatment of essential tremor Our initial study with 1-octanol at a low single dose in patients with essential tremor suggested it was both efficacious and safe
This present study is planned to identify a maximum tolerated dose and broaden the safety and efficacy data in humans Additionally we hope to collect further information about the pharmacokinetics of 1-octanol This study is designed as a phase Ia unblinded inpatient study of adults with essential tremor receiving escalating doses of 1-octanol Cohorts of three will begin dose escalation at the dose previously studied Each cohort will be followed in inpatient setting for 72 hours and outpatient for 1 additional week during which adverse events pharmacokinetics and efficacy will be assessed If no subject achieves dose-limiting toxicity 3 additional subjects will be recruited to receive the next higher dose If 13 subjects achieves dose-limiting toxicity the next cohort will receive the same dose Dose limiting toxicity is defined as the dose that produces dose-limiting toxicity in at least 2 subjects Maximum tolerated dose will be defined as the next lower dose
With this study we hope to identify a range of doses that may useful in the treatment of essential tremor and combined with the pharmacokinetic and efficacy data design a protocol to study multiple dose regimens over longer time periods
This present study is planned to identify a maximum tolerated dose and broaden the safety and efficacy data in humans Additionally we hope to collect further information about the pharmacokinetics of 1-octanol This study is designed as a phase Ia unblinded inpatient study of adults with essential tremor receiving escalating doses of 1-octanol Cohorts of three will begin dose escalation at the dose previously studied Each cohort will be followed in inpatient setting for 72 hours and outpatient for 1 additional week during which adverse events pharmacokinetics and efficacy will be assessed If no subject achieves dose-limiting toxicity 3 additional subjects will be recruited to receive the next higher dose If 13 subjects achieves dose-limiting toxicity the next cohort will receive the same dose Dose limiting toxicity is defined as the dose that produces dose-limiting toxicity in at least 2 subjects Maximum tolerated dose will be defined as the next lower dose
With this study we hope to identify a range of doses that may useful in the treatment of essential tremor and combined with the pharmacokinetic and efficacy data design a protocol to study multiple dose regimens over longer time periods
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 01-N-0178 | None | None | None |